Order Article Reprints

Chadderton N, Palfi A, Maloney DM, Carrigan M, Finnegan LK, Hanlon KS, Shortall C, O’Reilly M, Humphries P, Cassidy L, et al. Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction. Pharmaceutics. 2023; 15(2):322. https://doi.org/10.3390/pharmaceutics15020322

Chadderton, Naomi, Arpad Palfi, Daniel M. Maloney, Matthew Carrigan, Laura K. Finnegan, Killian S. Hanlon, Ciara Shortall, Mary O’Reilly, Peter Humphries, Lorraine Cassidy, and et al. 2023. "Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction" Pharmaceutics 15, no. 2: 322. https://doi.org/10.3390/pharmaceutics15020322

Chadderton, N., Palfi, A., Maloney, D. M., Carrigan, M., Finnegan, L. K., Hanlon, K. S., Shortall, C., O’Reilly, M., Humphries, P., Cassidy, L., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2023). Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction. Pharmaceutics, 15(2), 322. https://doi.org/10.3390/pharmaceutics15020322